A medical oncologist from Tulane University co-led the VISION trial, a study focusing on the use of a specific engineered radioactive molecule used to target prostate cancer cells and, hopefully, inhibit tumor growth in patients with advanced prostate cancer. Dr. Oliver Sartor co-led the international Phase 3 trial, the first one to investigate this particular approach in a quest to produce improvement in survival for prostate cancer patients. In this study, the investigators compared Novartis' Lu-PSMA-617, a targeted radioligand therapy, against the present-day standard of care for men with metastatic castration-resistant prostate cancer (mCRPC). The study revealed that the investigational therapy plus the standard of care significantly improves median survival (15.3 vs. 11.3 months) versus the standard of care alone. Overall, among patients in the study arm, tumors were more likely to shrink and PSA values more likely to fall in those patients that received the molecularly targeted radiation, reports Melanie Cross writing for Tulane News.
In this Phase 3 VISION trial (NCT03511664), the study team sought to compare the two alternative primary endpoints of radiogra...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).